Multidisciplinary management of advanced prostate cancer: Changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials

被引：8

作者：

Carducci, MA

Carroll, PR

机构：

[1] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA

[2] Univ Calif San Francisco, Sch Med, Dept Urol, UCSF Comprehens Canc Ctr, San Francisco, CA USA

来源：

UROLOGY | 2005年 / 65卷 / 5A期

关键词：

D O I：

10.1016/j.urology.2005.03.044

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Prostate cancer traditionally was managed by monotherapy, and treatment was almost exclusively provided by the urologic surgeon. As ongoing clinical trials in advanced disease identify novel agents or combination therapies with good tolerability and potential survival benefits, multidisciplinary management may offer optimal care for men with high-risk prostate cancer, as it does for women with breast cancer. Patients with high-risk recurrent or metastatic disease should be informed of. clinical trials for which they may be eligible.

引用

收藏

页码：18 / 22

页数：5

相关论文

共 23 条

[1]

Bettuzzi S, 2003, CANCER RES, V63, P3469

[2] Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer [J].

D'Amico, AV ;

Cote, K ;

Loffredo, M ;

Renshaw, AA ;

Schultz, D .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (23) :4567-4573

[3] Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].

D'Amico, AV ;

Moul, JW ;

Carroll, PR ;

Sun, L ;

Lubeck, D ;

Chen, MH .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383

[4] Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy [J].

D'Amico, AV ;

Chen, MH ;

Roehl, KA ;

Catalona, WJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :125-135

[5] National cooperative group trials [J].

DiPaola, RS ;

Thompson, IM .

UROLOGY, 2005, 65 (5A) :23-29

[6] Gene expression profiling predicts clinical outcome of prostate cancer [J].

Glinsky, GV ;

Glinskii, AB ;

Stephenson, AJ ;

Hoffman, RM ;

Gerald, WL .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 113 (06) :913-923

[7] Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy [J].

Kalapurakal, JA ;

Huang, CF ;

Neriamparampil, MM ;

Small, WJ ;

Pins, MR ;

Mittal, BB ;

Campbell, SC ;

Grayhack, JT ;

Shetty, RM .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (04) :1047-1054

[8] Gene expression profiling identifies clinically relevant subtypes of prostate cancer [J].

Lapointe, J ;

Li, C ;

Higgins, JP ;

van de Rijn, M ;

Bair, E ;

Montgomery, K ;

Ferrari, M ;

Egevad, L ;

Rayford, W ;

Bergerheim, U ;

Ekman, P ;

DeMarzo, AM ;

Tibshirani, R ;

Botstein, D ;

Brown, PO ;

Brooks, JD ;

Pollack, JR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (03) :811-816

[9]

Latil A, 2003, CLIN CANCER RES, V9, P5477

[10] Radiotherapy after radical prostatectomy: Treatment outcomes and failure patterns [J].

Nudell, DM ;

Grossfeld, GD ;

Weinberg, VK ;

Roach, M ;

Carroll, PR .

UROLOGY, 1999, 54 (06) :1049-1057